Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2019 Dec;54(12):2117-2119.
doi: 10.1038/s41409-019-0507-3.

Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)

Paul Richardson  1 , Saurabh Aggarwal  2 , Ozlem Topaloglu  3 , Kathleen F Villa  4 , Selim Corbacioglu  5
Affiliations
Published Erratum

Publisher Correction: Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)

Paul Richardson et al. Bone Marrow Transplant. 2019 Dec.

Abstract

The original version of this article included some minor typesetting errors in Table 1-a corrected version of which is provided in this correction article and has been corrected in the original article-and one error in text, which has been corrected in the original article. Furthermore, the article was erroneously published with the copyright holders as 'Springer Nature Limited', however, since the article is Open Access, the copyright holders should in fact be 'The Author(s)'. This has also been corrected in the original article.

PubMed Disclaimer

Erratum for

References

    1. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998;92:737–44. - PubMed
    1. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol. 2000;111:1122–9. doi: 10.1046/j.1365-2141.2000.02475.x. - DOI - PubMed
    1. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100:4337–43. doi: 10.1182/blood-2002-04-1216. - DOI - PubMed
    1. Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant. 2004;33:189–95. doi: 10.1038/sj.bmt.1704329. - DOI - PubMed
    1. Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer. 2007;48:700–4. doi: 10.1002/pbc.20934. - DOI - PubMed

Publication types